Meeting
2015 Gastrointestinal Cancers Symposium
GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).
Authors
John A. Bridgewater
UCL Cancer Institute, University College London, London, United Kingdom
John A. Bridgewater , Andres Cervantes , Ben Markman , Salvatore Siena , Antonio Cubillo , Rocio Garcia Carbonero , Darren Sigal , Giuseppe Aprile , David Cunningham , Cristina Nadal , Carles Pericay , Leslie M. Samuel , Daniel Hochhauser , Jose Alejandro Perez-Fidalgo , Andrew Strickland , Cecile Guizani , Sophie Golding , Vanesa Lopez Valverde , Marion Gabriele Ott , Josep Tabernero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01326000
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 669)
DOI
10.1200/jco.2015.33.3_suppl.669
Abstract #
669
Poster Bd #
D11
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: Additional study of E-Rechallenge Trial.
First Author: Yoshihito Ohhara
Poster
2016 ASCO Annual Meeting
Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.
First Author: Marc Peeters
Poster
2016 Gastrointestinal Cancers Symposium
Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.
First Author: Marc Peeters
Poster
2015 ASCO Annual Meeting
Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial).
First Author: Marlies Michl